HLN - Haleon Group Debt to Book Capitalization Ratio

Brandmark of Haleon plc (HLN)

The total debt-to-equity ratio highlights the stability of Haleon plc (HLN) regional plants, which minimize maritime shipping. The value 0.49 represents the current level of this metric. The company generates revenue from the sale of well-known vitamin and oral hygiene brands. Furthermore, the optimization of pharmacy distribution and a global warehouse network guarantee supply chain resilience and high profitability.

haleon.com - HLN Debts to Book Capitalization (period 04/28/2023 - 10/28/2026)
Flagship merchandise of Haleon Corp

This ratio measures the proportion of debt relative to book equity, allowing investors to assess financial stability and the risk of excessive leverage. By analyzing the capital structure trend—debt to book capitalization—one can determine how effectively Haleon plc balances financial security with the use of leverage for expansion in emerging markets and the digitalization of sales.

Competitors of Haleon plc

Debt to Book Capitalization Ratio Kenvue Inc.|veronapharma.com - Debt to Net Assets Ratio|MENS: Debt to Book Capitalization Ratio|LGND - Debt to Book Value|AMRX: Debts to Book Capitalization|Debts to Book Capitalization Perrigo Corp|ALVO - Debt to Book Value|Debt to Net Assets Ratio LQDA|Galapagos - Debt to Book Capitalization Ratio|Debts to Book Value ANI Pharmaceuticals Inc ANIP|Debt to Book Value MannKind Corp. (MNKD)|Debt to Book Capital Amphastar Corp AMPH|Debts to Book Capitalization Pacira BioSciences (PCRX)|SPRY - Debt to Net Assets Ratio|Debts to Book Capitalization TBPH|AQST (Aquestive Therapeutics Inc) - Debts to Book Value|SCPH - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Tectonic|Tonix Pharmaceuticals (TNXP) - Debts to Book Capitalization|Debt to Net Assets Ratio sxtchina.com (SXTC)|Debts to Book Capitalization EPRX (Eupraxia Pharmaceuticals Inc.)|BioHarvest Sciences, Inc. - Debts to Book Capitalization|EXOZ - Debt to Book Capitalization Ratio|ORMP - Debt to Book Capitalization Ratio|Debts to Book Capitalization ENTX|HYFT (ipatherapeutics.com) - Debts to Book Value|Debt to Book Capitalization Ratio ABVC (ABVC BioPharma, Inc.)|Debts to Book Value CPIX|Debt to Book Capitalization Ratio Quantum BioPharma Limited QNTM|Debt to Book Value Ratio FibroGen Corporation FGEN|Debt to Book Value Telomir Pharmaceuticals|Rani Therapeutics Holdings - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Synergy CHC Corporation|RLYB: Debts to Book Capitalization Ratio|lexariabioscience.com (LEXX) - Debt to Book Capitalization Ratio|Pulmatrix Corporation (PULM) - Debt to Book Capitalization Ratio|Debts to Book Capitalization PTHL|Debt to Book Value Aptorum|Lyra Therapeutics (LYRA) - Debts to Book Capitalization|Debt to Net Assets Ratio IBO (Impact BioMedical, Inc.)|Debt to Book Capitalization Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Debt to Book Capitalization Ratio|PainReform Ltd. (PRFX) - Debt to Book Capitalization Ratio|CYTO: Debt to Book Value Ratio|Debt to Book Capitalization Ratio Lipella Pharmaceuticals, Inc. (LIPO)|OptiNose Inc (OPTN) - Debts to Book Capitalization Ratio|PIRS - Debts to Book Capitalization|Debt to Net Assets Ratio Procaps Group Corp|Debts to Book Capitalization PTPI|Debts to Book Capitalization QLI (qlsyy.net)|Debt to Book Capitalization Ratio ACELYRIN|TFF Pharmaceuticals Inc. - Debt to Net Assets Ratio